Recent works have demonstrated that CDKN1B can be genetically inactivated and this occurs particularly in sporadic luminal breast cancer, prostate cancer and small intestine neuroendocrine tumors. The gene discussed is CDKN1B; the disease is neuroendocrine neoplasm.